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1. INTRODUCTION
Photodynamic therapy (PDT) is a minimally invasive clinical
procedure which holds great potential for treating many human
diseases including several conditions of the skin, age related
macular degradation and cancer.1 PDT can be used alone or in
combination with surgery, chemotherapy or ionizing radiation.
PDT can also be used to destroy undetected cancerous cells at the
margins of resection.2 In advanced cancers, PDT gives the option
of repeated treatments and allows clinicians to switch to more
aggressive treatments, if needed. To induce tumor destruction,
PDT requires three components: (i) a photosensitizer (PS)
localized in the neoplastic tissue, (ii) light of a particular wave-
length (to activate the PS), and (iii) oxygen. PSs are, in the
context of PDT, compounds that absorb light of a speciﬁc
wavelength and utilize that energy, in combinationwithmolecular
oxygen (3O2), to generate cytotoxic singlet oxygen (
1O2).
36
Various types of PSs have been synthesized in the last few
decades,3 and a few have been approved by drug administrations
for use in the clinic.7 However, some problems are associated with
existing PSs,8 including poor selectivity for tumor versus
peritumoral tissue, and suboptimal photophysical characteristics.
Hence, there is great interest in developing improved delivery
systems. The ideal system should incorporate the PS without loss
or alteration of PS activity and selectively accumulate the PS
within the tumor tissue with little or no uptake by nontarget cells.9
Nanoparticles represent a relatively new trend in drug
delivery.10,11 Large particles (>200 nm) are usually captured by
macrophages and typically exhibit a more rapid rate of clearance
than particles with radii under 200 nm.12 This can help to
maintain higher circulating levels of the therapeutic agents once
administered.13 Drugs or biosensors can be entrapped in the
nanoparticle matrix, conjugated to the nanoparticle surface or
covalently linked to the nanoparticle matrix. There are advan-
tages to entrapping drugs/sensors in the core of porous
nanoparticles.14 Primarily, the particle matrix acts as a barrier
between the intracellular environment and potentially toxic dyes,
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mulate in, tumor tissue by the enhanced permeability and
retention eﬀect, if sequestration by the reticuloendothelial
system (RES) is avoided. The application of nanoparticles in
the ﬁeld of drug delivery is thus an area of great interest, due to
their potential for delivering high payloads of drugs site
selectively. One area which may prove to be particularly
attractive is photodynamic therapy, as the reactive oxygen
species (ROS) which cause damage to the tumor tissue are
not generated until the drug is activated with light, minimizing
generalized toxicity and giving a high degree of spatial control
over the clinical eﬀect. In the present study, we have synthesized
two types of nanoparticles loaded with photodynamic sensiti-
zers: polylysine bound tetrasulfonato-aluminum phthalocya-
nine entrapped nanoparticles (PCNP) and polylysine bound
tetrasulfonato-aluminum phthalocyanine entrapped nanoparti-
cles coated with a second, porphyrin based, photosensitizer
(PCNP-P) to enhance the capacity for ROS generation, and hence therapeutic potential. The mean sizes of these particles were
45 ( 10 nm and 95 ( 10 nm respectively. Uptake of the nanoparticles by human Caucasian colon adenocarcinoma cells (HT29)
was determined by ﬂow cytometry and confocal microscopy. Cell viability assays using PCNP-P and PCNP corresponding to the
minimum uptake time (<5 min) and maximum uptake time (25 h) demonstrated that these cancer cells can be damaged by light
activation of these photodynamic nanoparticles both in the external media and after internalization. The results suggest that, in order
to induce photodynamic damage, the nanoparticles need only to be associated with the tumor cell closely enough to deliver singlet
oxygen: their internalization within target cells may not be necessary. Clinically, this could be of great importance as it may help to
combat the known ability of many cancer cells to actively expel conventional anticancer drugs.
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while inhibiting interactions between the dye and circulating
serum components, which could potentially alter the dye's
photophysical properties.
Endocytosis is one of the major pathways of nanoparticle
cellular uptake,1517 and this process is both concentration and
time dependent. Uptake of nanoparticles via endocytosis can
occur through phagocytosis, ﬂuid phase pinocytosis or receptor
mediated endocytosis. Nanoparticles less than 200 nm are
known to be imported into cells by pinocytosis while larger
particles (>500 nm) are internalized through phagocytosis.18
Panyam et al. reported no phagocytic activity with nanoparticles
approximately 100 nm in size.19
Exocytosis is the reverse process to endocytosis in eukaryotic
cells.20 Endocytosis and exocytosis are both dynamic and energy
dependent processes.19 At any point in time, the nanoparticle
concentrationwithin a cell results from the net diﬀerence between
these two processes. The intracellular population consists of
nanoparticles that are recycling inside the cell, in the lysosomes,
or in the cytoplasm.19 Jin et al. reported a comparison of
internalization (endocytotic uptake), exocytosis rates and net
accumulation of carbon nano tubes over time (8000 s) compiled
from single particle tracking and found that the net accumulation
ﬂuctuates with time.21
Nanoparticles used in drug delivery should be within the range
3200 nm.11 In targeting nanoparticles to tumor tissue, pro-
vided they can avoid sequestration by the reticuloendothelial
system (RES), accumulation can occur in the stroma as a result of
the enhanced permeability and retention eﬀect.22
Particles synthesized to avoid the RES can lead to longer
circulation times,23 resulting in greater potential to reach the site
of interest.24 These nanoparticles were approximately 100 nm in
size with a hydrophilic surface (to avoid clearance by ﬁxed
macrophages); this can be achieved by coating the particles with
hydrophilic polymers that create a cloud of chains on the particle
surface repelling plasma proteins.22
Polyacrylamide nanoparticles are hydrophilic and have demon-
strated potential in drug delivery.25 They have most commonly
been used to monitor intracellular analytes (Hþ, Ca2þ, Mg2þ,
Zn2þ, O2, Kþ, Naþ, Cl, OH, glucose)14,26,27 and metabolites.28
They have also been investigated as a delivery system for photo-
sensitizers29 with some successful results reported in vivo.30,31
In the present study, two types of polyacrylamide NPs
(Table 1) are used to study the PDT activity in the human
Caucasian colon adenocarcinoma cell line-HT29.
Physically entrapped dyes in polyacrylamide nanoparticles
have previously been reported to leach 4550% of their contents
in 48 h14,32 and up to 100% over seven days32 when in an aqueous
suspension. Factors such as the molecular size and hydrophilicity
of the dye play a signiﬁcant role in leaching properties of the dye
from a polyacrylamide matrix.32 Smaller dyes have a higher
tendency to diﬀuse through the pores of the matrix. Further,
hydrophobic dyes may have a tendency to stay near the surface of
the particle matrix. To overcome leaching problems, nanoparticle
pore size can be decreased by varying the type and the concentra-
tion of the cross-linker used in the nanoparticle synthesis,32
covalently attaching the dye to the nanoparticle matrix;33 or, by
adding cages or lipophilic tails27 to the dye. In this study, we have
minimized/overcome the leaching of the entrapped photosensi-
tizer by conjugating it to polylysine (MW 30,00070,000).
Nanoparticles accumulate in the stroma of tumors due to
selective retention.34 To eﬀect PDT, the nanoparticles need only
to be associated with the tumor cell closely enough to deliver
singlet oxygen and it may not be necessary that they are
internalized within the target cells.29 In order to investigate this
hypothesis we have irradiated HT29 cells with nanoparticles
present in the surroundingmedium, at the time corresponding to
minimum uptake time (<5 min), when <5% internalization has
occurred as determined by ﬂow cytometry. In order to compare
these results with those of maximal uptake, we have conducted
parallel experiments in which the same cells were incubated with
particles for the time corresponding to maximal uptake (25 h),
and irradiated after removing any particles remaining in the
external media. In this way we hoped to mimic in vivo scenarios
where particles have accumulated in the stroma surrounding the
Table 1. Type of Nanoparticles Synthesized
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cancer cells, but not penetrated them, and when particles have
been internalized by endocytosis.
Common delivery methods for internalizing polyacrylamide
nanoparticles into cells include liposomal delivery,32,35 gene
gun bombardment,35,36 and picoinjection.32,37,38 Further, speciﬁc
targeting of polyacrylamide nanoparticles can be achieved
by conjugating cell penetrating peptides to nanoparticles.39
Ingestion of nanoparticles into a cell involves their attachment
to the cell surface followed by internalization due to
endocytosis.19,4042 Although ingestion of polyacrylamide nano-
particles has been reported,37 as far as we are aware, this is the ﬁrst
attempt to qualitatively and quantitatively study polyacrylamide
nanoparticle uptake (by endocytosis) to assess their potential as a
delivery system for photodynamic sensitizers.
Nanoparticle uptake at regular intervals was quantiﬁed using
ﬂow cytometry. Confocal microscopy qualitatively conﬁrmed
nanoparticle internalization. Using this information, PDT in-
duced cytotoxicity was quantiﬁed at times of minimal and
maximum net uptake, in order to investigate the relative photo-
toxicity of the species when located in close proximity, but
external to the cell, and internalized within the cell.
2. MATERIALS AND METHODS
Materials. AlPc-tetrasulfonic acid was purchased from Fron-
tier Scientific. All the other reagents were purchased from Sigma
Aldrich and used as received unless otherwise stated.
Methods. Aluminum Phthalocyanine (AlPc) Tetrasulfonyl
Chloride Synthesis. AlPc-tetrasulfonic acid (200 mg, 0.23 mmol)
and chlorosulfonic acid (0.8 mL) were stirred for 3 h at 100 C.
Thionyl chloride (1.2 mL) was added followed by stirring for 2 h
at 80 C. Once cooled to room temperature, the solution was
poured onto ice and the AlPc-tetrasulfonyl chloride collected by
centrifugation and filtration and dried in vacuo to obtain the
product in 95% yield (0.22 g).
MW 30,00070,000 Polylysine Conjugated Phthalocyanine
(PC) Synthesis. AlPc-tetrasulfonyl chloride (100 mg, 0.1 mmol)
was added, in small portions, to a solution of poly-D-lysine
hydrobromide (MW30,00070,000) (50mg, 0.4 mmol, 4 equiv)
and sodium carbonate (85 mg, 0.8 mmol, 8 equiv) in water
(4 mL), while vortexing for 1 min between each addition. Ten
milliliters of the dispersion were dialyzed against PBS buffer using
ultra membrane filters (MWCO 14 000) over 4 days to remove
any unconjugated PC.MW30,00070,000 polylysine conjugated
PC was collected and dried in vacuo in 95% yield (104 mg).
MW 30,00070,000 Polylysine Conjugated PC Entrapped
Polyacrylamide Nanoparticle Synthesis. Pc-polylysine NPs were
synthesized by adopting the free radical microemulsion polymer-
ization procedure optimized by Josefsen et al.43 Briefly, a final
volume of 1.9 mL containing acrylamide (540 mg, 7.60 mmol)
and N,N0-methylenebisacrylamide (160 mg, 1.04 mmol) in water
(1.7 mL) followed by a solution (100 μL) of Pc polylysine (1.34
mol dm3) was added to a deoxygenated hexane (42mL) solution
containing Brij 30 (3.08 g, 8.49 mmol) and completely dissolved
dioctyl sulfosuccinate sodium salt (1.59 g, 3.58 mmol). A solution
(30 μL, 0.4382 mol dm3) of ammonium persulfate (100 mg,
0.4382 mmol) in water (1 mL) followed by TEMED (15 μL,
0.1 μmol) was added, and the reaction was stirred for 2 h under a
positive argon pressure at room temperature. Excess hexane was
removed in vacuo. The resulting viscous yellow colored solid was
washed with ethanol, centrifuged (8 50mL, 10 min, 4500 rpm)
and recovered by microfiltration (Whatman Anodisc 25, 0.02 μm,
25 mm filters) to yield the desired Pc polylysine entrapped
nanoparticles. Yield: 86% (602 mg).
MW 30,00070,000 Polylysine Conjugated AlPc Entrapped
Amino Functionalized Polyacrylamide Nanoparticle Synthesis.
To synthesize amino functionalized nanoparticles, the above
nanoparticle synthesis procedure was followed with the excep-
tion of addition of N-(3-aminopropyl)methacrylamide hydro-
chloride (1% equivalence to acrylamide) along with the
monomers. Briefly, a final volume of 1.900 mL containing
acrylamide (527 mg, 7.41 mmol), N,N0-methylenebisacrylamide
(160 mg, 1.04 mmol) and N-(3-aminopropyl)methacrylamide
hydrochloride (13 mg, 0.073 mmol) in water (1.7 mL) followed
by a solution 100 μL of Pc polylysine (1.34mol dm3) was added
to a deoxygenated hexane (42 mL) solution containing Brij 30
(3.08 g, 8.49 mmol) and completely dissolved dioctyl sulfosuc-
cinate sodium salt (1.59 g, 3.58mmol). A solution (30μL, 0.4382
mol dm3) of ammonium persulfate (100 mg, 0.4382 mmol) in
water (1mL) followed by TEMED (15 μL, 0.1 μmol) was added,
and the reaction was stirred for 2 h under a positive argon
pressure at room temperature. Excess hexane was removed in
vacuo. The resulting viscous yellow colored solid was washed
with ethanol, centrifuged (8  50 mL, 10 min, 4500 rpm) and
recovered by microfiltration (Whatman Anodisc 25, 0.02 μm,
25 mm filters) to yield the desired Pc polylysine entrapped
nanoparticles. Yield: 88% (616 mg).
5-(4-Carboxyphenyl)-10,15,20-tri-(4-pyridyl)porphyrin.44
Dropwise, pyrrole (4 mL, 57.8 mmol) was added to a refluxing
mixture of 4-formylbenzoic acid (2.54 g, 17 mmol) and 4-pyr-
idinecarboxaldehyde (9.78 mL, 104 mmol) in acetic acid
(200 mL) and nitrobenzene (150 mL). The reaction mixture
was kept under reflux and intense stirring for 1 h. The solvents
were removed under reduced pressure, and the residue was
purified by column chromatography using a mixture of 15%
dichloromethane/methanol as an eluent system. Pure 5-(4-
carboxyphenyl)-10,15,20-tri-(4-pyridyl)porphyrin was obtained
after precipitation from methanol over chloroform in 6% in yield
(510 mg).
5-[4-(Succinimide-N-oxycarbonyl)phenyl]-10,15,20-tri-(4-
pyridyl)porphyrin45. To a stirred solution of 5-(4-carboxy-
phenyl)-10,15,20-tri-(4-pyridyl)porphyrin (51.1 mg, 0.077
mmol) in dry pyridine (5 mL) was slowly added thionyl chloride
(0.1 mL, 1.37 mmol, 18 equiv). The reaction was stirred at 50 C,
protected from light and atmospheric moisture, for 30 min. N-
Hydroxysuccinimide (200 mg, 1.74 mmol, 22.6 equiv) was then
added, and the mixture was kept stirring under the previous
conditions for a further 3 h. Pyridine was then removed under
vacuum and the residue taken up in dichloromethane andwashed
with an aqueous saturated solution of sodium carbonate. The
organic layer was dried over sodium sulfate and evaporated
to dryness under reduced pressure. Crystallization of the residue
in light petroleum over chloroform afforded pure 5-[4-
(succinimide-N-oxycarbonyl)phenyl]-10,15,20-tri-(4-pyridyl)
porphyrin in 90% yield (52.3 mg). 1H NMR (CDCl3, 400 MHz)
δ: 2.90 (br s, 2H, NH), 3.03 (br s, 4H, CH2), 8.17 (dd, 6H,
10,15,20-H-Ar-o, J 1.6, 4.3 Hz), 8.37 (dd, 2H, 5-H-Ar-m, J 1.7, 6.5
Hz), 8.57 (dd, 2H, 5-H-Ar-o, J 1.7, 6.5Hz), 8.85 (d, 2H,H-β, J 4.8
Hz), 8.868.90 (m, 6H, H-β), 9.06 (dd, 6H, 10,15,20-H-Ar-m,
J 1.6, 4.3 Hz). 13C NMR (CDCl3, 400 MHz) δ: δ: 25.8, 30.0
(CH2), 117.8, 129.1, 129.3 (10,15,20-Ar-o-C), 134.8, 148.4 (10,
15,20-Ar-m-C),149.8, 150.2, 162.0 (CO2N), 169.3 (CON).
Mass (MALDI): m/z 759. UVvis: 420, 519, 555, 580,
636 nm.
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5-[4-(Succinimide-N-oxycarbonyl)phenyl]-10,15,20-tris-(4-
N-methylpyridimiumyl)porphyrin Triiodide45. To a stirred solu-
tion of 5-[4-(succinimide-N-oxycarbonyl)phenyl]-10,15,20-
tri-(4-pyridyl)porphyrin (26 mg, 0.0343 mmol) in dry DMF
(5 mL) was added a large excess of methyl iodide (0.5 mL, 8.03
mmol) via syringe. The reaction mixture was kept stirring at
40 C, under a nitrogen atmosphere and protected from light
overnight. The product was then precipitated with diethyl
ether to remove any trace of methyl iodide and DMF. The
resulting solid was filtered and dissolved in acetone/water
(50:50), and the solvents were removed under reduced pressure.
Pure 5-[4-(succinimide-N-oxycarbonyl)phenyl]-10,15,20-tris-
(4-N-methylpyridimiumyl)porphyrin triiodide was obtained after
a new precipitation in acetone over water in 89% yield (31.6 mg).
1H NMR (CDCl3, 400 MHz) δ: 3.05 (br s, 2H, NH), 3.01
(br s, 4H, CH2), 4.71 and 4.72 (2s, 6 þ 3H, CH3), 8.50 (d, 2H,
5-H-Ar-m, J 8.3 Hz), 8.60 (d, 2H, 5-H-Ar-o, J 8.3 Hz), 9.00 (d, 6H,
10,15,20-H-Ar-o, J 6.6 Hz), 9.049.13 and 9.149.22 (2 m, 8H,
H-β), 9.48 (d, 6H, 10,15,20-H-Ar-m, J 6.6 Hz). Mass (MALDI):
m/z 804. UVvis: 420, 520, 554, 582, 635 nm.
5-[4-(Succinimide-N-oxycarbonyl)phenyl]-10,15,20-tris-(4-
N-methylpyridimiumyl)porphyrin Trichloride. To a solution
of 5-[4-(succinimide-N-oxycarbonyl)phenyl]-10,15,20-tris-(4-
N-methylpyridimiumyl)porphyrin triiodide (56.9 mg, 0.0481
mmol) in anhydrous methanol (57 mL) was added Dowex
18 200400 Cl (1.81 g), and the reaction mixture was stirred
at room temperature for 1 h, protected from moisture and light.
The resin was separated by filtration and the reaction mixture
concentrated under reduced pressure. After precipitation
with acetone, pure 5-[4-(succinimide-N-oxycarbonyl)phenyl]-
10,15,20-tris-(4-N-methylpyridimiumyl)porphyrin trichloride
was obtained as a brown solid in 96% yield (41.8 mg). 1H
NMR (DMSO-d6, 400 MHz) δ:3.05 (br s, 2H, NH), 3.01 (br
s, 4H, CH2), 4.72 and 4.73 (2s, 6þ 3H, CH3), 8.50 (d, 2H, 5-H-
Ar-m, J 8.0 Hz), 8.60 (d, 2H, 5-H-Ar-o, J 8.0 Hz), 9.00 (d, 6H,
10,15,20-H-Ar-o, J 5.6 Hz), 9.059.12 and 9.139.24 (2 m, 8H,
H-β), 9.49 (d, 6H, 10,15,20-H-Ar-m, J 5.6 Hz). 13C NMR
(DMSO-d6, 100 MHz) δ: 25.7 (CH2), 47.9 (CH3), 115.0,
115.5, 120.7, 124.6, 128.9, 132.1 (10,15,20-Ar-o-C), 135.1,
144.2 (10,15,20-Ar-m-C), 147.3, 156.4, 162.0 (CO2N), 170.5
(CON). Mass (MALDI): m/z 804. UVvis: 421, 519, 554, 584,
637 nm.
Conjugation of 5-[4-(Succinimide-N-oxycarbonyl)phenyl]-
10,15,20-tris-(4-N-methylpyridimiumyl)porphyrin Trichloride
to Polyacrylamide Nanoparticles. An aliquot of (500 μL, 2.2
mmol dm3) of succinimide-N-oxycarbonyl)phenyl]-10,15,20-
tri(4-N-methylpyridiniumyl porphyrin was added to a dispersion
(10 mL) of filtered (Millex GP, 0.22 μm Filter unit) amino
functionalized AlPc-polylysine entrapped nanoparticles (50 mg)
and triethylamine (250 μL). The mixture was spun in Falcon
polystyrene (12 75 mm) tubes for 2 h on a spinning rotator at
room temperature, protected from light. The resulting suspen-
sion was washed with ethanol, centrifuged (7  50 mL, 10 min,
5500 rpm), microfiltered (Whatman Anodisc 25, 0.02 μm, 25
mm filters) and dried for 8 h at 40 C to yield the desired
porphyrin conjugated PC entrapped nanoparticles as a green
solid. Yield: 78% (39 mg).
Characterization of Nanoparticles. Particle Size. The par-
ticle size and size distribution properties of the nanoparticles
were measured by PCS, Zetaplus particle size analyzer (Malvern
3000) at 25 C and at a scattering angle of 90. A dilute sample of
nanoparticles (1 mg/mL) was prepared in Milli-Q water,
sonicated for 30s and filtered (Millex GP, 0.22 μm filter unit)
before analysis. The value was recorded as the average of 30 data
measurements.
TEM Imaging.The nanoparticles were suspended in deionized
water and placed in an ultrasonic bath for 3 min. The suspension
was then passed through a Millex GP, 0.22 μm filter unit and the
resulting suspension returned to the ultrasonic bath for a further
2 min to disperse any aggregates. Five microliters of the suspen-
sion was immediately put onto a hydrophilic carbon coated
copper grid (Agar Scientific Ltd., Stansted, Essex, U.K.) and
allowed to air-dry. Dry ethanol (5 μL) was then added to the grid
and left to air-dry. TEM images were obtained using anUltraScan
4000 digital camera (Gatan UK, Abingdon) attached to a Jeol
2010 transmission electron microscope (Jeol (UK) Ltd. Welwyn
Garden City) running at 120 kV.
Determination of the Entrapped Phthalocyanine (PC) Con-
centration and the Conjugated Photosensitizer Concentration.
One milligram of filtered (Millex GP, 0.22 μm filter unit)
nanoparticles was dispersed in 1 mL of deionized water and
the absorbance of the particles measured by UV spectrophoto-
metry (Varian Cary50 Bio; Cary WinUV) between the wave-
lengths 400 and 800 nm.
The concentrations of the entrapped Pc and Porphyrin
concentration were quantiﬁed using the BeerLambert law
(A = εCL; A, absorbance; ε, extinction coeﬃcient of the
compound; C, concentration; L, path length). The reported
extinction coeﬃcient for Al-Pc calculated from absorbance at
666 nm is 1.5  105 M1 cm1, and the measured extinction
coeﬃcient for NHS porphyrin calculated from absorbance at
520 nm is 2.3  105 M1 cm1.
Leaching of Entrapped PC Polylysine from the Nanoparti-
cles. Leaching of the PC-polylysine from the nanoparticles was
studied to assess the porosity of the nanoparticles. Nanoparticles
(200 mg) were dispersed in 80 mL of Milli-Q water. The
dispersion was kept stirring at room temperature. At given time
intervals (hourly), three 2 mL samples were drawn from the
suspension and the nanoparticles were microfiltered (Whatman
Anodisc 25, 0.02 μm, 25 mm filter). The filtrate was analyzed by
fluorescence microscopy.
Determination of Singlet Oxygen Production. Two milli-
liters of DCM followed by 3 mL of cholesterol 10 mM (1:9
DCM:MeOH) was added to a nanoparticle (5 mg/1 mL
MeOH) suspension. Oxygen was bubbled through the resulting
suspension mixture, which was then irradiated with white light
(400700 nm) for one hour. The mixture volume was reduced
to dryness by flowing argon into the suspension. Onemilliliter of
MeOH was added, and the suspension was filtered through a
15 nm filter (Whatman Nuclepore track-etched membrane;
25 mm, 0.015 μm). 200 μL of this solution was transferred to
an Eppendorf (tube), and 200 μL of methanol was added. 12
crystals of NaBH4 were added to the solution, which was left for
1 min until complete reduction had taken place. The volume of
the solvent was reduced to approximately 100150 μL by
flowing argon over the solution.
TLC plate development was carried out using the method
described by van Lier et al.46 Brieﬂy, a TLC plate was placed in a
tank containing 1:1 hexane:ethyl acetate mixture. The solvent
was allowed tomigrate 2/3 of the way up the plate; the plate was
then removed from the TLC chamber and allowed to air-dry.
Once dried, the plate was returned to the tank and the solvent
was allowed to migrate to the top of the plate and was left dry
again. To visualize the sterols on the TLC plate, a 5% H2SO4 in
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ethanol mist was sprayed onto the TLC plate and the plate
placed on a 100120 C hot plate to allow development of the
colored spots.
The HPLC method for quantifying the singlet oxygen
production was adopted from Osada et al.47 Cholesterol and
its oxidative derivatives were separated on a Phenomenex
Luna 5 μm C18 column (250  4.60 mm) using a mixture of
methanol:acetonitrile (60:40 vol/vol) mobile phase. The ﬂow
rate was maintained at 1.0 mL/min for 20 min prior to
analysis. UV detection was performed at 205 nm. Tenmicroliters
of the sample was injected manually into the HPLC analysis
system, and the separation was detected using the Azur
software.
Cell Line Experiments. Cell Culture. HT29 cells were routi-
nely cultured in 75 cm3 tissue culture flasks in McCoy’s 5A
medium supplemented with 10% fetal calf serum (FCS), 1% L-
glutamine (all purchased from PAA) at 37 C in a humidified
environment of 5% CO2. The medium was replenished every
day, and the cells were subcultured after reaching confluence.
PBS, BSA, and sodium azide were purchased from Sigma
Aldrich, U.K.
Cellular Uptake (FACS) of Nanoparticles. The cell uptake of
PCNP nanoparticles was studied using HT29. This cell line was
selected due to the large amount of data published on PDT
effects of photosensitizers using these cells.
A time course experiment was carried out by setting up a
control (cells only) and 2 samples (cells and nanoparticles) at
each given time point. Cell-only controls contained 50,000 cells
in 400 μL of McCoy’s high glucose medium, and each sample
contained 50,000 HT29 cells and 10mg of polylysine conjugated
phthalocyanine entrapped nanoparticles in 400 μL of medium
(10 mg of nanoparticle suspension in 200 μL of medium was
added to a sterile Falcon polystyrene (12  75 mm) tube
containing 50,000 cells in 200 μL of medium).
Both the control and sample systems were incubated at 37 C,
in an atmosphere of 5% CO2 within a humidiﬁed incubator. At
given time points, duplicate sample tubes and a control tube were
taken out of the incubator, washed, and resuspended in ice cold
PBS/BSA/azide solution before preparation of the material for
ﬂow cytometry.
Following incubation, 4 mL of the PBS/BSA/azide solution
was added to all three tubes, and the cells were pelleted by
centrifugation at 404g for 5 min. The supernatant was removed
and discarded, and the cells were resuspended in 1 mL of PBS/
BSA/azide solution and transferred to a clean tube. The cells
were washed again by adding a further 3 mL of PBS/BSA/azide.
The cells were pelleted once again by centrifugation at 404g
for 5 min. The washing procedure was repeated twice more,
before the cells were resuspended in 200 μL of PBS/BSA/azide
solution.
The cell suspension was loaded into a hemocytometer after
5 min to count the cells. Results were then acquired using a
Becton Dickinson FACS Calibur ﬂow cytometer with the
following settings: forward scatter (FSC) E 1 752, side scatter
(SSC) 369; ﬂuorescence (FL1) log 412; ﬂuorescence (FL2) log
474, ﬂuorescence (FL3) log 427, ﬂuorescence (FL4) log 377.
A minimum of 10,000 cells was measured in each sample.
PCNP were detected in the ﬂuorescence level (FL4) channel
of the ﬂow cytometer. Analysis was performed using CellQuest
Pro V software (BectonDickinson), and histograms were plotted
of FL4 ﬂuorescence versus cell counts for each time point. The
cell-only sample provided the negative control at each time point.
Photocytotoxicity: In Vitro HT 29 Cells (Maximum Uptake).
Ten milligrams of nanoparticles was added to 1 mL of McCoy’s
medium, vortexed (60 s), sonicated (60 s) and filtered (Millex
GP, 0.22 μm filter unit). The obtained volume (approximately
800 μL) was added to the same volume of cells (2.5 105 cells/
1 mL) in a Falcon polystyrene (12 75 mm) tube. The tube was
incubated for 25 h at 37 C in a humidified environment of 5%
CO2. The volume of the medium was increased to 4 mL, and
after centrifugation, the supernatant was discarded to eliminate
any interference from nanoparticle conjugates that had not been
internalized or attached to the HT29 cells. The volume of
medium was increased to the initial volume (approximately
800 μL). HT29 cells were plated with 100 μL of cell suspension
per well in two 96 well plates. The two controls, cells only (100%
cell survival) and medium only (background control) were
plated onto each plate.
One plate was irradiated with 7 J/cm2 [∼23 min] followed by
a 40 min recovery period in the incubator (at 37 C in a
humidiﬁed environment of 5% CO2) and another 7 J/cm
2 using
an Oriel light system (>580 nm red schott glass ﬁlter, 51310/
59510). The second plate was kept in the dark outside the
incubator while the other plate was being irradiated. The plates
were left to incubate overnight for 1824 h in the dark. To
determine cell viability, the colorimetric MTT (3-[4, 5-di-
methylthiazol-2-yl]-2,5-diphenyltetrazolium bromide; Sigma
Aldrich) metabolic activity assay developed by Mossman,48 and
subsequently modiﬁed by Prasad and co-workers to incorporate
a cell irradiation protocol,49 was used. The cell viability was
determined using a microplate reader (BioTek EL 800).
Photocytotoxicity: In Vitro Photodynamic Therapy Experi-
ments with HT 29 Cells (Minimum Uptake). Nanoparticles and
cells were prepared and plated as above and without incubating
the cells with nanoparticles or washing prior to irradiation. The
light control plate was irradiated with the same system described
above soon after plating (<5 min) 7 J/cm2 [∼23 min] followed
by a 40 min recovery period in the incubator (at 37 C in a
humidified environment of 5% CO2) and another 7 J/cm
2.
Meanwhile the dark control plate was kept outside the incubator
in the dark. The controls, cells only (100% cell survival) and
medium only (background control), were each plated in a 96
well plate.
The wells were washed with 3 100 μL of medium. 100 μL of
medium was added to the wells, and the plates were left to
incubate overnight for 1824 h in the dark. MTT activity assays
were used as above to determine cell viability.
Fluorescence Confocal Microscopy. One milliliter of PCNP
(10 mg/mL) and PCNP-P (10 mg/mL) was added to separate
Falcon polystyrene (12 75 mm) tubes containing 1 mL (2.5
105/mL) of HT29. These were incubated for 20 h at 37 C in a
Chart 1. PCNP Absorbance and Emission Spectra
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humidified environment of 5% CO2 and washed three times with
McCoy’s medium.
The intracellular localization of the nanoparticles was ob-
served with a Leica Microsystems CMS Gmbh (LAS AF version:
2.2.1 build 4842). To observe the PCNP the incubated cells with
PCNP were excited at 633 nm and the emission was collected
between 648 and 790 nm. Similarly, PCNP-P localization was
observed by exciting the incubated cells with PCNP-P at 405 nm
and 633 nm and emission collected between 420 and 790 nm and
between 648 and 794 nm respectively.
3. RESULTS AND DISCUSSION
Nanoparticle Synthesis and Characterization. PC-polyly-
sine (MW 30,00070,000) entrapped polyacrylamide nanopar-
ticles were synthesized by adopting the well documented
microemulsion polymerization method used in previous
work from this laboratory43 and others.37 The polylysine was
conjugated to PC to minimize leaching once entrapped in the
polyacrylamide matrix. The absorbance and emission spectra
confirmed that the PC is entrapped intact within the nanoparticle
matrix (Chart 1).
It should be noted that all the nanoparticle suspensions were
prepared in deionized water and ﬁltered through a Millex GP,
0.22 μm ﬁlter unit prior to any preliminary characterizations or
secondary experiments unless stated otherwise.
The mean particle size, 45 ((10 nm), was determined by PCS
and TEM images (TEM, Figure 1). Amino functionalization of
the PCNP-A was conﬁrmed using a ﬂuoroscamine test.50
Leaching of the PCNP was studied using ﬂuorescence spec-
troscopy. This technique was used due to its high sensitivity
(approximately 1000 times more than absorption spectroscopy).
In the experiment, hourly, three 2 mL aliquots were drawn from
the suspension (200 mg of nanoparticles in 80 mL of Milli-Q
water), the nanoparticles were microﬁltered and the supernatant
was analyzed by ﬂuorescence microscopy. Maximum leaching of
the PC from the nanoparticles peaked at 3 h (Chart 2), and the
level of ﬂuorescence remained at the same level. This may suggest
that the majority of loosely trapped PCmolecules are “removed”
from the nanoparticle suspension within this time. The ﬂuores-
cence intensity of the ﬁltrate dropped slowly between 3 and 24 h.
Thus, it can be hypothesized that no further leaching occurred
after the ﬁrst three hours. The slight drop in the ﬂuorescence
level of the ﬁltrate after three hours could be due to photo-
bleaching due to the much smaller concentration of ﬂuorescent
material (PC) in the ﬁltrate. Amino functionalized PCNP oﬀered
a similar observation.
To synthesize the PCNP-P, PCNP-A (in suspension) was
mixed with synthetic porphyrin engineered to bear a single
amine-reactive succinimide-N-oxycarbonyl-phenyl group in
water for one hour. The nanoparticles were then precipitated
and washed (5 times, 50 mL) with ethanol.
Successful conjugation of 5-[4-(succinimide-N-oxycarbonyl)-
phenyl]-10,15,20-tri(4-N-methylpyridiniumyl porphyrin) to
PCNP-A was conﬁrmed by clear absorbance peaks at 424 nm
(porphyrin, Soret band) and 680 nm (PC, Q-band) respectively.
When excited at 424 nm, the PCNP-P emission spectrum
showed two clear ﬂuorescence peaks (656 and 708 nm) corre-
sponding to the porphyrin and a minor peak relative to PC at
685 nm. However, when excited at 650 nm (close to the PC λmax
of 680 nm), a clear emission peak relating to the PC at 685 nm
was observed (Chart 3).
As conﬁrmed by the PCS and TEM images, the mean size of
the PCNP-P was 95( 10 nm (Figure 1). The size of a porphyrin
molecule is 18 Å, and thus the maximum size increase that was
expected was ∼36 Å. Experiments were carried out to study the
reasons for this unexpected increase in size of PCNP-A after
conjugation to the porphyrin molecule.
One hypothesis was that the increase in the mean particle size
upon porphyrin conjugation to PCNPs could be a result of
Chart 2. Leached Fluorescence over Time: Phthalocyanine Conjugated Polylysine (MW 30,00070,000) Entrapped
Nanoparticles
Figure 1. TEM - PCNP, PCNP-P.
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aggregation caused by porphyrin interactions on adjacent parti-
cles. This type of ππ interaction could be detected in the
ﬂuorescence spectra of the NHS porphyrin used for conjugation,
and is similar to the split ﬂuorescence peaks reported for
these interactions with the related 5,10,15,20-tetrakis(4-N-
methylpyridyl)porphyrin51(Chart 4).
Polyacrylamide hydrogels/nanogels are known to swell in
aqueous environments.52 Thus, an alternative hypothesis was that
this eﬀect was due to polyacrylamide swelling. In water, the swelling
is controlled by several factors: the cross-linker concentration, pH
and ionic strength.52,53 However, experiments carried out to study
whether the diameter increase was a result of this swelling
behavior indicated that these parameters were not involved.
Leaching studies carried out with the PCNP-P showed no
ﬁltrate ﬂuorescence; two photosensitizers (PC and porphyrin)
were successfully conjugated to a polyacrylamide nanoparticle
system (without leaching).
Absorbance spectra for one milligram of each PCNP-P
and PCNP-A were compared to observe any diﬀerences in
the PC concentration. The Q-band of PCNP-P showed a
slight decrease (1520%) of intensity compared to PCNP-A
(Chart 5).
This could be either because any loosely entrapped PC was
washed away during the conjugation procedure and/or the mass
added by the conjugated porphyrin in the total weighed sample.
The porphyrinnanoparticle conjugation procedure generally
takes approximately 3 h, and PC leached only in the ﬁrst 3 h.
During the conjugation procedure, it is possible that any loosely
entrapped PC was washed away, leaving only the tightly en-
trapped PC in the nanoparticle.
The concentrations of the entrapped PC and porphyrin
were quantiﬁed using the BeerLambert law: 1.9  104 M
with respect to PC for PCNP-A and 1.6  104 M mol of PC
and 1.8 104 M for PC and porphyrin, respectively, for PCNP-P.
The drug loading of the batches reproduced using the stated
concentrated was within standard deviation 5.09  108 (within
30%).
Nanoparticle Uptake. We have found that polyacrylamide
nanoparticles do accumulate in cells, provided they are incubated
with cells for a sufficient time period. Following this, we studied
the fluctuation of the nanoparticle net uptake by flow cytometry
over 28 h using PCNP with HT29 cells incubated at 37 C in a
humidified environment of 5% CO2 (Chart 6). At every hour for
the duration of the experiment, duplicate sample tubes and a
control tube were taken out of the incubator, washed and
resuspended in ice cold PBS/BSA/azide solution before pre-
paration for flow cytometry.
Since both endocytosis and exocytosis are energy dependent
functions,17 ice cold washing steps were considered to have a
minimal54 and/or constant eﬀect on nanoparticle uptake study.
Further, it should be noted that the HT29 cell line used in the
experiment naturally divides with time eﬀectively reducing the
quantity of nanoparticles in each cell by a factor of 2 with each
division,32 which could potentially have an impact on the
internalization studies. Two concentrations (3 mg/mL and
5 mg/mL) of nanoparticles were studied, and the percentage
Chart 3. PCNP-P Absorbance and Emission Spectra
Chart 4. Fluorescence Spectrum of 5,10,15,20-Tetrakis(4-N-
methylpyridyl)porphyrina
aNHS porphyrin emission (Ex: 424 nm).
Chart 5. PCNP-A and PCNP-P Absorbance Spectra
Comparisona
a1 mg of NPs; in 3 mL of water.
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uptake values conﬁrmed that nanoparticle uptake by HT29 was
concentration dependent (Chart 6).
According to the quantiﬁed NP uptake proﬁle, NP uptake
reaches its maximum in 18 h and then remains constant, but with
regular ﬂuctuations. Alberola et al. showed a similar oscillation
pattern in uptake of nanoparticles by epithelial cells using
ﬂuorescence microscopy.55
The same concentration (5 mg/1 mL) of both PCNP-A and
PCNP-P demonstrated a similar, but more intense, ﬂuctuation
pattern as for PCNP (Chart 7).
All three nanoparticle types showed a relatively high uptake at
25 h. Thus, in the PDT cytotoxicity assays, cells were incubated
with nanoparticles for 25 h before irradiation.
The cytotoxic agent in PDT is singlet oxygen. TLC
(qualitatively) and HPLC (quantitatively) conﬁrmed the singlet
oxygen production by both NP types. PCNP-P produced 20%
more singlet oxygen in comparison to PCNP.
PDT: Cytotoxicity Assays. Nanoparticles suspended in
McCoys 5A medium were filtered through a 220 nm filter prior
to any PDT cytotoxicity experiments as a sterilizing step. In
cytotoxicity assays, generally ethanol is used to sterilize
particles prior to incubation with cells. However, it is known
that ethanol has the potential to disrupt the cell mem-
branes even when present in small quantities,56 and in the
study, it was found that this caused unpredicted cell toxicity
when incubating for longer periods, therefore its use was
avoided.
The ﬁltered high intensity (1000 W) quartztungsten halo-
gen light system (>580 nm red SCHOTT glass ﬁlter, 51310/
59510) with water cooling was used to compare the PDT activity
of PCNP and PCNP-P. NPs were incubated for 25 h with HT29,
and the cells were irradiated with 7 J/cm2 [∼23min] followed by
40 min recovery period in the incubator and another 7 J/cm2
irradiation. The light dose (14 J/cm2) was fractionated with a 40
min recovery period to allow reoxygenation of the media. The
plates were left in the incubator overnight for 1824 h in the
dark. MTT activity assays were then used to determine the cell
viability.
Chart 6. PCNP Net Uptake with HT29 over Time
Chart 7. PCNP, PC NP (Amino), PC Porphyrin NP: Net Uptake with HT29 over Time
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After irradiation cell viability of PCNP-P was 20% while the
nonirradiated dark control was 91%. Cell viability of the PCNP
following irradiation was 30% and the dark control was 70%
(Chart 8).
Russell et al.57 reported cell viability, after irradiation, of 43%
and viability of 77% for an analogous experiment without
irradiation with gold nanoparticles coated on the surface with
phthalocyanines (diameter 24 nm). In this case, HeLa cells
were incubated with the nanoparticles for 4 h, and irradiated with
light at 690 nm (1.84 mW cm2) for 20 min.
Nanoparticles are reported to accumulate in tumor neovascu-
lature due to selective retention.34 Exploiting this notion in vitro,
HT29 cells surrounded with nanoparticles, in the extracellular
media, and at theminimum uptake time (<5min) were irradiated
under identical conditions to those used for the 25 h uptake time.
MTT assays were then performed as before and cell viabilities
determined (Chart 9).
PCNP-P showed the lowest cell viability post irradiation with
only 3.7% of cells surviving, whereas the cell viability of PCNP
was 33%. However, no noticeable dark toxicity was observed with
either PCNP or PCNP-P. This result could be due to, in this
instance, the nanoparticles being mixed with cells only for the
duration of the irradiation (approximately 90 min).
These results are potentially very interesting from a clinical
perspective, as it is likely that a signiﬁcant proportion of
nanoparticles would accumulate in the stroma of the tumor i.e.
in the extracellular space. We have demonstrated here that, if this
localized concentration is high enough, cancer cells can be
eﬀectively killed without the requirement that they be
internalized.
Intracellular Distribution of Nanoparticles. According to
the cell uptake studies, the maximum uptake of nanoparticles
should have been reached in 18 h. The confocal microscopy
images below display the localization of the NPs, PCNP and
PCNP-P which have been incubated with HT29 cells for 20 h
and washed three times with media prior to imaging. The
confocal images were captured at 633 nm (Figure 2), and 633
and 405 nm (Figure 3).
Although, the PC absorbs signiﬁcantly at approximately
400 nm, excitation at 405 nm gave no ﬂuorescence from the
PCNP. Thus, the ﬂuorescence observed with PCNP-P
(excited at 405 nm) was considered to be only that emitted
by porphyrin.
As can be seen from Figure 3, cells show granular ﬂuorescence
(PC and porphyrin), suggesting localization of the nanoparticles
in endocytic vessels.58
Chart 8. PCNP and PCNP-P: PDT Cytotoxicity (Maximum Uptake)a
a25 h incubation; irradiation, 14 J cm2.
Chart 9. PCNP and PCNP-P: PDT Cytotoxicity (Minimum Uptake)a
a0 h incubation; irradiation, 14 J cm2.
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Figure 2. Confocal images of PCNP internalized in HT29 cells (after incubating for 20 h): (A) HT29 cells only, (B) PC emission, and (C)
merged image.
Figure 3. Confocal images (Leica) of PCNP-P internalized in HT29 cells (after incubating for 20 h) (red, excited at 633 nm; green, excited at 405 nm):
(A) PC emission, (B) porphyrin emission, (C) HT29 cells only, and (D) merged image.
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4. CONCLUSIONS
The results presented here indicate that polyacrylamide
nanoparticles have potential as delivery vehicles for photody-
namic agents in photodynamic therapy for cancer. Both intern-
ally trapped photosensitizers and analogues with a second
photosensitizer conjugated to the particles after formation were
active against HT-29 cells, but the latter was the more powerful
PDT agent when the particles were internalized. The ability to
deliver more than one class of photosensitizer could be advanta-
geous clinically, as the larger spectral region covered could lead to
more eﬃcient absorption of light. The ability to deliver more
than one class of photosensitizer could be advantageous clini-
cally, as the larger spectral region covered could lead to more
eﬃcient absorption of light. The cationic nature of PCNP-P also
makes it potentially attractive for photodynamic antimicrobial
chemotherapy (PACT).
Results also show that cellular internalization is not necessary
to photodynamically kill cancer cells, although internalized
particles are also active; this could be important as in vivo
signiﬁcant amounts of nanoparticle would be expected to accu-
mulate in the extracellular space in tumors due to the enhanced
permeability and retention eﬀect.
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